Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of H1/IC31 in HIV-infected adults without tuberculosis
PACTR201105000289276Phase 2Completed
- Sponsor
- Statens Serum Institut
- Start
- Jan 2012
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Tuberculosis (TB) comparing H1/IC31 with Placebo (2 arms). Primary endpoints: Safety and Immunogenicity. Started Jan 2012; status: completed.
02
Drugs
Ag85B-ESAT-6 + IC31
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on PACTR201105000289276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201105000289276.